Skip to content

Ulmus Macrocarpa Hance Extract and Lipid Profile

Effect of Ulmus Macrocarpa Hance Extract on Lipid Profile in Adults With Dyslipidemia: a RCT

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03773315
Enrollment
80
Registered
2018-12-12
Start date
2018-12-01
Completion date
2020-02-28
Last updated
2021-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemias

Brief summary

The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of the Ulmus Macrocarpa Hance extract on lipid profile in adults with dyslipidemia for 12 weeks.

Detailed description

Previous another our study have indicated that Ulmus Macrocarpa Hance extract (UMH) may have the ability to decrease blood cholesterol. Therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of the UMH on lipid profile in adults with dyslipidemia; the safety of the compound are also evaluate. The Investigators examine total cholesterol, HDL-cholesterol, triglyceridemia, LDL-cholesterol, and other biochemical parameters at baseline, as well as after 6 and 12 weeks of intervention. Eighty adults were administered either 500 mg of UMH or a placebo each day for 12 weeks;

Interventions

DIETARY_SUPPLEMENTPlacebo

Starch placebo 500 mg/day for 12 weeks

DIETARY_SUPPLEMENTUMH extract

Schisandra chinensis extract 500 mg/day for 12 weeks

Sponsors

Sang Yeoup Lee
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* LDL cholesterol ranging from 130 to 190 mg/dL

Exclusion criteria

* Abnormal liver or renal function (i.e., serum aminotransferase activity \> 80 IU/L and serum creatinine concentrations \> 1.2 mg/dL) * Diabetes (diagnosed clinically or fasting glucose level \> 126 mg/dL) * History of ischemic heart disease or cerebrovascular disease * Uncontrolled hypertension * History of serious cardiac disease such as angina or myocardial infarction * History of gastrectomy * History of medication for psychiatric disease * Administration of oriental medicine including herbs within the past 4 weeks

Design outcomes

Primary

MeasureTime frameDescription
LDL cholesterol12 weeksLDL cholesterol

Secondary

MeasureTime frameDescription
Total cholesterol12 weeksTotal cholesterol
Triglyceride12 weeksTriglyceride
HDL cholesterol12 weeksHDL cholesterol

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026